arrow
O

Oğuzhan Yıldız

Necmettin Erbakan University
H指数:1
被引数:6

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey

一线度伐利尤单抗–特瑞普利单抗治疗晚期肝细胞癌:来自土耳其的真实世界数据

2026-08-020
OA
Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study

在EGFR突变NSCLC发生SCLC转化后,联合免疫疗法与化疗可能改善生存:一项多中心真实世界研究

2026-08-010
PRE
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

brigatinib 在晚期ALK阳性NSCLC中的真实世界有效性与安全性:土耳其肿瘤学组进行的一项全国多中心研究

2026-02-110
PRE
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

卡博替尼与舒尼替尼在晚期非透明细胞肾细胞癌中的真实世界比较:土耳其肿瘤学集团的多中心研究

2025-09-010
PRE